CaryHealth has introduced its direct-to-patient (DTP) platform, intended to streamline patient access.
The platform is claimed to aid in transforming the patient journey from clinical and telehealth consultations through to delivery, as well as providing adherence support.
It integrates real-time data tracking and pharmacy fulfilment across the entire patient experience.
By integrating AI-driven engagement with the supply chain of its nationally licensed pharmacy, the platform is stated to provide an end-to-end service.
This integration helps streamline access for patients while providing manufacturers with the assurance that therapies are delivered to patients safely, at scale, and consistently.
CaryHealth’s clinical sequencing engine provides personalised engagement at every interaction point. This ensures that patients receive support and connection, thereby significantly increasing their likelihood of adhering to treatment.
Manufacturers obtain insights via the CaryConnect dashboard, which includes dynamic reporting and A/B testing to enhance patient outreach and programme performance.
The platform utilises an enterprise-grade data fabric alongside an agentic automation layer. This approach allows pharmaceutical manufacturers to decrease the time to first fill and improve adherence by means of continuous experience optimisation.
CaryHealth CEO and co-founder Areo Nazari said: “While the shift towards the direct-to-patient model is inevitable, its success hinges on reimagining the patient journey, not just traditional distribution.
“CaryHealth delivers a customisable and unified digital experience where every touchpoint is connected, personalised, and powered by modern UI/UX [user interface/experience] frameworks. Too many DTP experiences today are fragmented as a result of using multiple digital engagement vendors.
“By integrating digital experience, clinical engagement, scalable supply chain orchestration and actionable data, our platform builds patient trust, drives adherence and helps therapies achieve their full potential.”
